Limits...
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL - J. Exp. Med. (2001)

Bottom Line: IL-12 treatment strongly increased the cell vaccine efficacy.Specific anti-HER-2/neu antibodies were produced and a nonpolarized activation of CD4(+) and CD8(+) cells secreting IL-4 and interferon (IFN)-gamma were evident.In conclusion, our data show that an allogeneic HER-2/neu-expressing cell vaccine combined with IL-12 systemic treatment can prevent the onset of genetically determined tumors.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research Section, Department of Experimental Pathology, University of Bologna, Italy.

ABSTRACT
Transgenic Balb/c mice expressing the transforming rat HER-2/neu oncogene develop early and multifocal mammary carcinomas. Within the first 5 months of life the tissue-specific expression of HER-2/neu causes a progression in all their 10 mammary glands from atypical hyperplasia to invasive carcinoma. It was previously observed that chronic administration of interleukin (IL)-12 increased tumor latency, but every mouse eventually succumbed to multiple carcinomas. A significant improvement in tumor prevention was sought by administering allogeneic mammary carcinoma cells expressing HER-2/neu combined with systemic IL-12. This treatment reduced tumor incidence by 90% and more than doubled mouse lifetime. For the maximum prevention p185(neu) antigen must be expressed by allogeneic cells. IL-12 treatment strongly increased the cell vaccine efficacy. The mammary glands of mice receiving the combined treatment displayed a markedly reduced epithelial cell proliferation, angiogenesis, and HER-2/neu expression, while the few hyperplastic foci were heavily infiltrated by granulocytes, macrophages, and CD8(+) lymphocytes. Specific anti-HER-2/neu antibodies were produced and a nonpolarized activation of CD4(+) and CD8(+) cells secreting IL-4 and interferon (IFN)-gamma were evident. A central role for IFN-gamma in the preventive effect was proven by the lack of efficacy of vaccination in IFN-gamma gene knockout HER-2/neu transgenic Balb/c mice. A possible requirement for IFN-gamma is related to its effect on antibody production, in particular on IgG2a and IgG2b subclasses, that were not induced in IFN-gamma knockout HER-2/neu mice. In conclusion, our data show that an allogeneic HER-2/neu-expressing cell vaccine combined with IL-12 systemic treatment can prevent the onset of genetically determined tumors.

Show MeSH

Related in: MedlinePlus

Cytofluorometric analysis of HER-2/neu and MHC class I glycoprotein expression in Neu/H-2q cells. Open profiles represent cells stained with secondary antibody alone; solid profiles represent cells incubated with the indicated antibodies. In each panel, the ordinate represents the number of cells. Data from an experiment representative of at least three similar experiments are shown.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2195980&req=5

fig1: Cytofluorometric analysis of HER-2/neu and MHC class I glycoprotein expression in Neu/H-2q cells. Open profiles represent cells stained with secondary antibody alone; solid profiles represent cells incubated with the indicated antibodies. In each panel, the ordinate represents the number of cells. Data from an experiment representative of at least three similar experiments are shown.

Mentions: Vaccination with allogeneic mammary carcinoma cells (Neu/H-2q) expressing high surface levels of both p185neu and H-2q class I molecules (Fig. 1) followed by intraperitoneal administration of IL-12 was used to halt mammary carcinogenesis in Balb-neuT mice. IL-12 was chosen because of its ability to significantly delay tumor onset (1, 2). Beginning when the mice were 6 wk old, they received Neu/H-2q cells twice-weekly in the first and second week, followed by five daily administrations of IL-12 in the third week. After 1 wk of rest this course was repeated until mice were killed or reached the age of 1 y.


Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL - J. Exp. Med. (2001)

Cytofluorometric analysis of HER-2/neu and MHC class I glycoprotein expression in Neu/H-2q cells. Open profiles represent cells stained with secondary antibody alone; solid profiles represent cells incubated with the indicated antibodies. In each panel, the ordinate represents the number of cells. Data from an experiment representative of at least three similar experiments are shown.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2195980&req=5

fig1: Cytofluorometric analysis of HER-2/neu and MHC class I glycoprotein expression in Neu/H-2q cells. Open profiles represent cells stained with secondary antibody alone; solid profiles represent cells incubated with the indicated antibodies. In each panel, the ordinate represents the number of cells. Data from an experiment representative of at least three similar experiments are shown.
Mentions: Vaccination with allogeneic mammary carcinoma cells (Neu/H-2q) expressing high surface levels of both p185neu and H-2q class I molecules (Fig. 1) followed by intraperitoneal administration of IL-12 was used to halt mammary carcinogenesis in Balb-neuT mice. IL-12 was chosen because of its ability to significantly delay tumor onset (1, 2). Beginning when the mice were 6 wk old, they received Neu/H-2q cells twice-weekly in the first and second week, followed by five daily administrations of IL-12 in the third week. After 1 wk of rest this course was repeated until mice were killed or reached the age of 1 y.

Bottom Line: IL-12 treatment strongly increased the cell vaccine efficacy.Specific anti-HER-2/neu antibodies were produced and a nonpolarized activation of CD4(+) and CD8(+) cells secreting IL-4 and interferon (IFN)-gamma were evident.In conclusion, our data show that an allogeneic HER-2/neu-expressing cell vaccine combined with IL-12 systemic treatment can prevent the onset of genetically determined tumors.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research Section, Department of Experimental Pathology, University of Bologna, Italy.

ABSTRACT
Transgenic Balb/c mice expressing the transforming rat HER-2/neu oncogene develop early and multifocal mammary carcinomas. Within the first 5 months of life the tissue-specific expression of HER-2/neu causes a progression in all their 10 mammary glands from atypical hyperplasia to invasive carcinoma. It was previously observed that chronic administration of interleukin (IL)-12 increased tumor latency, but every mouse eventually succumbed to multiple carcinomas. A significant improvement in tumor prevention was sought by administering allogeneic mammary carcinoma cells expressing HER-2/neu combined with systemic IL-12. This treatment reduced tumor incidence by 90% and more than doubled mouse lifetime. For the maximum prevention p185(neu) antigen must be expressed by allogeneic cells. IL-12 treatment strongly increased the cell vaccine efficacy. The mammary glands of mice receiving the combined treatment displayed a markedly reduced epithelial cell proliferation, angiogenesis, and HER-2/neu expression, while the few hyperplastic foci were heavily infiltrated by granulocytes, macrophages, and CD8(+) lymphocytes. Specific anti-HER-2/neu antibodies were produced and a nonpolarized activation of CD4(+) and CD8(+) cells secreting IL-4 and interferon (IFN)-gamma were evident. A central role for IFN-gamma in the preventive effect was proven by the lack of efficacy of vaccination in IFN-gamma gene knockout HER-2/neu transgenic Balb/c mice. A possible requirement for IFN-gamma is related to its effect on antibody production, in particular on IgG2a and IgG2b subclasses, that were not induced in IFN-gamma knockout HER-2/neu mice. In conclusion, our data show that an allogeneic HER-2/neu-expressing cell vaccine combined with IL-12 systemic treatment can prevent the onset of genetically determined tumors.

Show MeSH
Related in: MedlinePlus